Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Enoximone in status asthmaticus

Oscar Schulz, Olaf Wiesner, Tobias Welte, Benjamin-Alexander Bollmann, Hendrik Suhling, Marius M. Hoeper, Markus Busch
ERJ Open Research 2020 6: 00367-2019; DOI: 10.1183/23120541.00367-2019
Oscar Schulz
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Oscar-schulz@web.de
Olaf Wiesner
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Welte
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tobias Welte
Benjamin-Alexander Bollmann
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrik Suhling
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marius M. Hoeper
1Dept of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marius M. Hoeper
Markus Busch
2Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In a patient with severe status asthmaticus, enoximone, a phosphodiesterase-3 inhibitor, caused immediate bronchodilation http://bit.ly/38UYpUn

To the Editor:

Bronchial asthma is a chronic disease affecting >300 million people worldwide [1]. The most severe disease manifestation is status asthmaticus, which can be unresponsive to medical therapy. Patients with severe status asthmaticus who require intubation and mechanical ventilation have mortality rates of up to 20% [2]. Airflow obstruction is often so severe that adequate decarboxylation and protective ventilation are not feasible, and extracorporeal membrane oxygenation (ECMO) support is nowadays an established treatment option as a bridge to recovery [3, 4].

In 2014, Beute [5] described a series of eight patients with status asthmaticus refractory to standard treatment in whom enoximone, a phosphodiesterase (PDE)-3 inhibitor, caused immediate bronchodilatation. To the best of our knowledge, these observations have not yet been confirmed by others. We here report a case of a patient with refractory status asthmaticus who showed rapid and sustained bronchodilation after intravenous administration of enoximone.

A 54-year-old female patient was transferred to our intensive care unit from another hospital with refractory status asthmaticus. The otherwise healthy patient had been diagnosed with mild allergic bronchial asthma for >10 years. Her symptoms were well controlled with formoterol as needed. The patient had been admitted to another hospital 1 day earlier with severe asthma symptoms refractory to treatment with high-dose systematic corticosteroids, magnesium, parenteral and inhaled β2-agonists, an inhaled muscarinic receptor antagonist, and inhaled adrenaline. Intubation was required but mechanical ventilation proved almost impossible due to severe airflow obstruction. Upon arrival at our centre, arterial blood gas analysis showed a carbon dioxide tension of 144 mmHg and severe acidosis with a pH of 6.9 (minute ventilation volume of 1 L with a peak inspiratory pressure (Pinsp) of 43 cmH2O, a positive end-expiratory pressure (PEEP) of 8 cmH2O and an inspiratory oxygen fraction (FIO2) of 100%). Venovenous ECMO was instituted immediately, which allowed for effective decarboxylation and protective ventilation (pressure controlled, FIO2 40%, Pinsp 27 cmH2O, PEEP 11 cmH2O and respiratory rate 11 per min). The patient was sedated with isoflurane, ketamine and propofol. Antiobstructive treatment was continued with systemic corticosteroids, inhaled β2-agonists and antimuscarinergic agents.

Over the next 3 days, the clinical situation was stable but severe airflow obstruction persisted, so we decided to try enoximone based on the aforementioned case series [5]. As this compound is no longer readily available, it took 24 h to deliver, during which time the patient's airflow obstruction had slightly improved but continued to be severe (figure 1). Enoximone was administered intravenously starting with a bolus infusion of 0.5 mg·kg−1 over 20 min followed by a constant infusion rate of 5 µg·kg−1·min−1, based on the prescribing information and the previous experience reported by Beute [5]. Within 15 min after start of treatment, expiratory flow improved and the tidal volume increased from 470 to 561 mL (figure 1). Pinsp was gradually decreased from 16 to 10 cmH2O over the next 10 h. Besides an increase in heart rate by ∼10 beats per min, no discernible side-effects were observed. Over the next 3 days, airflow obstruction resolved (figure 1) and enoximone was gradually weaned off over a period of 12 h. The ECMO was removed on the third day after enoximone was started and the patient was extubated a few hours later on the same day. Another 3 days later, the patient was transferred to a normal ward.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Screenshots from the ventilator. Pressure (top, yellow), flow (middle, green) and volume (bottom, blue) curves with corresponding ventilator settings and tidal volume measurements a) immediately before administration of enoximone, b) 15 min after enoximone had been started and c) 3 days later, immediately before extubation. Ppeak: peak inspiratory pressure; Pmittel: mean airway pressure; PEEP: positive end-expiratory pressure; AF: respiratory rate; O2: inspiratory oxygen fraction; MVe: expiratory minute volume; TVi: inspiratory tidal volume; TVe: expiratory tidal volume.

Enoximone was originally developed for the treatment of severe heart failure [6]. Because of its relatively short plasma half-life of ∼60 min, the drug is usually administered via continuous parenteral infusion [7]. Enoximone acts as an inotrope by inhibiting PDE-3 activity and increasing intracellular cAMP concentrations in cardiac myocytes [7]. Increasing intracellular cAMP is also the main mechanism of β2-agonists in patients with bronchial asthma [7]. As in our case, patients with status asthmaticus are usually unresponsive to β2-agonists, at least partly due to receptor desensitisation [4]. In experimental models of allergic asthma, enoximone has bronchodilatory and anti-inflammatory effects, yielding a biological rationale for using this compound in patients with severe asthma [8].

Protective ventilation with the use of ECMO or extracorporeal carbon dioxide removal has become a mainstay in treating patients with severe status asthmaticus, and the majority of patients eventually recover [9]. In our patient, we saw the first signs of recovery at the time when we started enoximone, so we do not claim that this drug was lifesaving in our patient. Nevertheless, we feel that it is important to communicate this case, as the rapid and sustained response to enoximone suggests that this compound (and perhaps other PDE-3 inhibitors) may have a potential therapeutic role in patients with severe asthma. This hypothesis is supported by recent data on the use of inhaled PDE-3 inhibitors in patients with bronchial asthma [10]. Together, these findings warrant further exploration of the therapeutic potential of PDE-3 inhibitors in this patient population.

Footnotes

  • Conflict of interest: O. Schulz has nothing to disclose.

  • Conflict of interest: O. Wiesner has nothing to disclose.

  • Conflict of interest: T. Welte has nothing to disclose.

  • Conflict of interest: B-A. Bollmann has nothing to disclose.

  • Conflict of interest: H. Suhling has nothing to disclose.

  • Conflict of interest: M.M. Hoeper reports personal fees for lectures and consultation from Actelion, Bayer, MSD and Pfizer, outside the submitted work.

  • Conflict of interest: M. Busch has nothing to disclose.

  • Received December 23, 2019.
  • Accepted February 18, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    The Global Asthma Report 2018. Auckland, Global Asthma Network, 2018.
  2. ↵
    1. Afessa B,
    2. Morales I,
    3. Cury JD
    . Clinical course and outcome of patients admitted to an ICU for status asthmaticus. Chest 2001; 120: 1616–1621. doi:10.1378/chest.120.5.1616
    OpenUrlCrossRefPubMed
  3. ↵
    1. Strid JM,
    2. Gammelager H,
    3. Johansen MB, et al.
    Hospitalization rate and 30-day mortality among patients with status asthmaticus in Denmark: a 16-year nationwide population-based cohort study. Clin Epidemiol 2013; 5: 345–355. doi:10.2147/CLEP.S47679
    OpenUrl
  4. ↵
    1. Wong JJ,
    2. Lee JH,
    3. Turner DA, et al.
    A review of the use of adjunctive therapies in severe acute asthma exacerbation in critically ill children. Expert Rev Respir Med 2014; 8: 423–441. doi:10.1586/17476348.2014.915752
    OpenUrl
  5. ↵
    1. Beute J
    . Emergency treatment of status asthmaticus with enoximone. Br J Anaesth 2014; 112: 1105–1108. doi:10.1093/bja/aeu048
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bader FM,
    2. Gilbert EM,
    3. Mehta NA, et al.
    Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail 2010; 16: 265–270. doi:10.1111/j.1751-7133.2010.00185.x
    OpenUrlCrossRefPubMed
  7. ↵
    1. Boswell-Smith V,
    2. Spina D,
    3. Page CP
    . Phosphodiesterase inhibitors. Br J Pharmacol 2006; 147: Suppl. 1, S252–S257.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Beute J,
    2. Lukkes M,
    3. Koekoek EP, et al.
    A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight 2018; 3: 94888. doi:10.1172/jci.insight.94888
    OpenUrl
  9. ↵
    1. Yeo HJ,
    2. Kim D,
    3. Jeon D, et al.
    Extracorporeal membrane oxygenation for life-threatening asthma refractory to mechanical ventilation: analysis of the Extracorporeal Life Support Organization registry. Crit Care 2017; 21: 297–297. doi:10.1186/s13054-017-1886-8
    OpenUrl
  10. ↵
    1. Franciosi LG,
    2. Diamant Z,
    3. Banner KH, et al.
    Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013; 1: 714–727. doi:10.1016/S2213-2600(13)70187-5
    OpenUrl
PreviousNext
Back to top
Vol 6 Issue 1 Table of Contents
ERJ Open Research: 6 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Enoximone in status asthmaticus
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Enoximone in status asthmaticus
Oscar Schulz, Olaf Wiesner, Tobias Welte, Benjamin-Alexander Bollmann, Hendrik Suhling, Marius M. Hoeper, Markus Busch
ERJ Open Research Jan 2020, 6 (1) 00367-2019; DOI: 10.1183/23120541.00367-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enoximone in status asthmaticus
Oscar Schulz, Olaf Wiesner, Tobias Welte, Benjamin-Alexander Bollmann, Hendrik Suhling, Marius M. Hoeper, Markus Busch
ERJ Open Research Jan 2020, 6 (1) 00367-2019; DOI: 10.1183/23120541.00367-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Procoagulant microparticles and COVID-19
  • Cancer referral and interventional pulmonology during COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society